MARKET

ABUS

ABUS

Arbutus Biopharm
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.940
-0.090
-2.97%
After Hours: 2.920 -0.02 -0.68% 19:55 09/23 EDT
OPEN
3.010
PREV CLOSE
3.030
HIGH
3.054
LOW
2.870
VOLUME
1.48M
TURNOVER
--
52 WEEK HIGH
9.02
52 WEEK LOW
0.8214
MARKET CAP
237.87M
P/E (TTM)
-1.1944
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Arbutus Reports Positive Hepatitis B Data, And Other News: The Good, Bad And Ugly Of Biopharma
Arbutus reports positive data for AB-729 for chronic hepatitis B.Marinus Pharmaceuticals hits primary endpoint in Genetic Epilepsy trial.Novus Therapeutics on upswing on Anelixis acquisition.
Seekingalpha · 1d ago
Arbutus Announces AB-729 90 mg Single-Dose Week 12 Data in Chronic Hepatitis B Subjects Demonstrating Significant and Continuous Reductions in HBsAg
Mean HBsAg reduction of 1.23 log10 IU/mL at week 12 with a favorable safety and tolerability profile WARMINSTER, Pa., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic
GlobeNewswire · 09/15 11:30
Arbutus to Participate in Virtual Fireside Chat at H.C. Wainwright 22nd Annual Global Investment Conference
WARMINSTER, Pa., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including COVID-19
GlobeNewswire · 09/09 13:00
DISH, ARDX, BBQ and AHT among after-hours movers
Gainers: [[DISH]] +6.2%. [[ARDX]] +5.5%. [[CCH]] +5.1%. [[BBW]] +3.7%. [[LPRO]] +3.5%. Losers: [[BBQ]] -6.5%. [[FTSI]] -4.9%. [[LBTYK]] -4.3%. [[ABUS]] -4.3%. [[AHT]] -3.5%.
Seekingalpha · 08/28 21:51
Arbutus Biopharma files for $200M mixed shelf
Arbutus Biopharma (ABUS) has filed a prospectus for a $200M mixed shelf offering.Shares down 6% after hours.
Seekingalpha · 08/28 20:19
Assembly Biosciences and Arbutus Biopharma Announce Clinical Collaboration Agreement to Evaluate the Combination of Core Inhibitor ABI-H0731 with RNAi Therapeutic AB-729 in Patients with Chronic Hepatitis B Virus Infection
SOUTH SAN FRANCISCO, Calif. and WARMINSTER, Pa., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB) and Arbutus Biopharma Corporation (Nasdaq: ABUS), today announced that the companies have entered into a clinical collaboration agreement to evaluate Assembly’s lead hepatitis
GlobeNewswire · 08/27 13:00
Assembly Biosciences teams up with Arbutus Biopharma in chronic HBV infection
Assembly Biosciences (ASMB) has announced a clinical collaboration with Arbutus Biopharma (ABUS) to evaluate Assembly’s ABI-H0731 in combination with Arbutus’ AB-729 and standard-of-care nucleos(t)ide reverse transcriptase inhibitor (NrtI) therapy for chronic HBV infection.Phase
Seekingalpha · 08/27 12:33
ABT, CLVS among premarket gainers
Moxian (MOXC) +52% on merger with Btab.VBI Vaccines (VBIV) +38%.ZAGG (ZAGG) +21% as InvisibleShield screen protection with exclusive partner Kastus anti-microbial technology confirmed to kill human coronavirus.ReneSola (SOL) +20% on
Seekingalpha · 08/27 12:21
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ABUS. Analyze the recent business situations of Arbutus Biopharm through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ABUS stock price target is 5.17 with a high estimate of 8.00 and a low estimate of 1.000.
EPS
Institutional Holdings
Institutions: 92
Institutional Holdings: 28.62M
% Owned: 35.38%
Shares Outstanding: 80.91M
TypeInstitutionsShares
Increased
14
2.95M
New
21
-812.64K
Decreased
11
2.30M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.52%
Pharmaceuticals & Medical Research
-1.14%
Key Executives
Chairman/Independent Director
Frank Torti
President/Chief Executive Officer/Director
William Collier
Chief Financial Officer
David Hastings
Executive Vice President/Chief Compliance Officer/General Counsel
Elizabeth Howard
Chief Scientific Officer
Michael Sofia
Other
Michael McElhaugh
Other
Gaston Picchio
Independent Director
Daniel Burgess
Independent Director
Andrew Cheng
Independent Director
Richard Henriques
Independent Director
Keith Manchester
Independent Director
James Meyers
Independent Director
Eric Venker
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ABUS
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing cure for people with chronic hepatitis B virus (HBV) infection. Its product pipeline is focused on finding curative combination regimen for chronic HBV infection, with the objective of developing a suite of products that intervene at different points in the viral life cycle and reactivate the host immune system. It is developing a product pipeline consisting of multiple drug candidates with complementary mechanisms of action. The Company’s HBV product pipeline includes ribonucleic acid (RNA) interference (RNAi) therapeutics, oral capsid inhibitors, oral compounds that inhibit programmed death-ligand one (PDL1) and oral HBV RNA destabilizers. Its subsidiaries include Arbutus Inc and Arbutus Biopharma US Holdings, Inc.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Arbutus Biopharma Corp stock information, including NASDAQ:ABUS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABUS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ABUS stock methods without spending real money on the virtual paper trading platform.